Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript

SA Transcripts 162.12K Followers Follow Structure Therapeutics Inc. ( GPCR ) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management September 8, 2026 8:30 AM EDT Company Participants Jennifer Robinson Raymond Stevens - CEO & Director Blai Coll - Chief Medical Officer Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Terence Flynn - Morgan Stanley, Research Division Jiale Song - Jefferies LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Patrick Dolezal - LifeSci Capital, LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Cameron DeGuzman - Wolfe Research, LLC Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Presentation Operator Good morning, and welcome to the Structure Therapeutics conference call. [Operator Instructions] Please be advised today's conference is being recorded. I would now like to turn the call over to Jen Robinson, Head of Investor Relations for Structure Therapeutics. Jennifer Robinson Thank you, and good morning. Earlier today, we issued a press release providing data updates from ACCG-2671, our oral small molecule dual amylin and calcitonin receptor agonist, and aleniglipron ACCESS open-label extension results. A copy of the press release and the presentation accompanying today's call are available in the Investor Relations section of Structure Therapeutics' website. I would like to remind everyone that some of the statements we will make on this call and information presented in the slide deck may include forward-looking statements, which you see here. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially. Please refer